OTC Watch

All stocks / ZIVO

Zivo Bioscience, Inc. ZIVO

Zivo Bioscience (ZIVO): no warning signs from our rules in the last 12 months and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated float OTCIDMichigan, USA
Live quote on OTC Markets

Market listing

Full name
ZIVO BIOSCIENCE INC
Market tier
OTC Pink Current
Trading status
Active
Last trade
09:48:01
Website
www.zivobioscience.com/
Source: Stockwatch, 2026-11-17

News headlines

Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
2026-05-12 10:09 · News Release
ZIVO Bioscience Secures Commercial-Scale Manufacturing Agreement with Cyanotech Corporation for Zivolife(TM) Algal Biomass
2026-04-06 08:00 · News Release
ZIVO Bioscience Provides Special Letter to Shareholders
2026-03-27 16:43 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2024-12-31
The report says
Revenue
$157,220
Net loss
($13,384,836)
What it means

It spends more than it earns

Under strain

Customers paid it $157,220 in the year. It lost $13.4 million. For every $1 that came in, about $86.13 went out.

The report says
Cash and cash equivalents
$1,542,442
Net cash used in operating activities
($4,313,510)
What it means

The cash could run out soon

Under strain

It had $1.5 million in the bank and used about $359,459 a month. At that pace the money lasts about 4 months unless it borrows or sells more shares.

The report says
Total assets
$1,643,122
Total liabilities
$2,158,019
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $1.6 million. Its debts and unpaid bills add up to $2.2 million. That is about $1.31 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2025-11-09

Estimated float about 1,913,647 shares as of 2025-11-09: 3,888,595 outstanding minus 1,974,948 held by 5 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Shares outstanding

Source: SEC filings
2024-12-31
3.6M
2025-03-12
3.8M
2025-03-31
3.8M
2025-05-10
3.8M
2025-06-30
3.8M
2025-08-09
3.8M
2025-09-30
3.8M
2025-11-09
3.9M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-04-24 4
2026-04-01 EFFECT
2026-03-31 POS AMPOS AM
2026-03-31 S-8 POSS-8
2026-03-31 15-12G15-12G
2026-03-30 8-KFORM 8-K
2026-03-03 4PRIMARY DOCUMENT
2026-02-27 SCHEDULE 13D/A
2026-02-17 4
2026-02-12 4PRIMARY DOCUMENT
2026-01-28 4PRIMARY DOCUMENT
2026-01-28 4PRIMARY DOCUMENT

Common questions about ZIVO

Does ZIVO file reports with the SEC?

Yes. Zivo Bioscience files with the SEC under company number 0001101026. The most recent filing we hold is a 4 dated 2026-04-24.

Source record

How many ZIVO shares are outstanding?

3,888,595 shares as of 2025-11-09, as reported to the SEC.

Source record

Has ZIVO filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Who runs Zivo Bioscience?

Officers named in its insider filings: John Bernard Payne (President and CEO) and William A. Sullivan (Chief Financial Officer).

Source record

Is Zivo Bioscience making money?

Customers paid it $157,220 in the year. It lost $13.4 million. For every $1 that came in, about $86.13 went out. (Annual figures to 2024-12-31. Facts from the company's own report, not a recommendation.)

Source record